Genitourinary cancers (GUC) include a broad spectrum of cancers affecting genitourinary organs. GUC are prevalent worldwide and ageing probably contributes to the rising incidence of GUC. More particularly, the population of advanced GUC has presented a rapid growth, leading to a high annual death rate. The treatments of advanced GUC have evolved dramatically over the last decade including novel immunotherapies and genome-targeted treatments. However, these treatments are still non-curative but along with the aim of prolonging life, relieving symptoms and improving quality of life. More efforts should be made to explore optimal therapeutic approaches against advanced GUC.
Tumor resection is potentially curative for patients with primary GUC in situ and single- or oligometastatic resectable disease. For those with advanced/metastatic GUC, cytoreductive surgery (CS) is mostly palliative and systemic therapies are necessary. CS is attempted to reduce the number of cancer cells of primary tumor or metastatic deposits, mainly to minimize tumor burden and relieve symptoms. Recently, CS has attracted considerable attention in the treatment of advanced GUC to achieve a better clinical benefit. The cytoreduction-systemic therapies combination has been proved effective to increase the cancer-specific survival rates and overall survival rates in patients with GUC such as metastatic renal cell carcinoma and metastatic prostate cancer. However, this therapeutic option is still in the experimental phase with controversial results. Further studies are imperative to determine the therapeutic efficacy of CS for patients with GUC.
The aim of this topic is to highlight state-of-art research findings of CS therapies in advanced GUC as well as to provide convincing evidence on its application strategy. In this topic, we warmly welcome original research and review articles related to all fields to address the use of CS in GUC treatments.
Authors are welcomed to submit their manuscripts focusing on but not only limited to:
- Novel therapeutic approaches with cytoreduction for treatment of advanced genitourinary cancers
- Follow-up outcomes of GUC patients after GS treatment: RCTs, cohort studies, case series, etc.
- Prognostic evaluation models for advanced genitourinary cancers undergoing cytoreductive surgery
- Novel animal models to study cytoreduction treatments for advanced genitourinary cancers
- Novel imaging techniques to assess therapeutic effects of cytoreduction
- Postulated mechanisms of cancer progression after cytoreductive surgery for advanced genitourinary cancers
Genitourinary cancers (GUC) include a broad spectrum of cancers affecting genitourinary organs. GUC are prevalent worldwide and ageing probably contributes to the rising incidence of GUC. More particularly, the population of advanced GUC has presented a rapid growth, leading to a high annual death rate. The treatments of advanced GUC have evolved dramatically over the last decade including novel immunotherapies and genome-targeted treatments. However, these treatments are still non-curative but along with the aim of prolonging life, relieving symptoms and improving quality of life. More efforts should be made to explore optimal therapeutic approaches against advanced GUC.
Tumor resection is potentially curative for patients with primary GUC in situ and single- or oligometastatic resectable disease. For those with advanced/metastatic GUC, cytoreductive surgery (CS) is mostly palliative and systemic therapies are necessary. CS is attempted to reduce the number of cancer cells of primary tumor or metastatic deposits, mainly to minimize tumor burden and relieve symptoms. Recently, CS has attracted considerable attention in the treatment of advanced GUC to achieve a better clinical benefit. The cytoreduction-systemic therapies combination has been proved effective to increase the cancer-specific survival rates and overall survival rates in patients with GUC such as metastatic renal cell carcinoma and metastatic prostate cancer. However, this therapeutic option is still in the experimental phase with controversial results. Further studies are imperative to determine the therapeutic efficacy of CS for patients with GUC.
The aim of this topic is to highlight state-of-art research findings of CS therapies in advanced GUC as well as to provide convincing evidence on its application strategy. In this topic, we warmly welcome original research and review articles related to all fields to address the use of CS in GUC treatments.
Authors are welcomed to submit their manuscripts focusing on but not only limited to:
- Novel therapeutic approaches with cytoreduction for treatment of advanced genitourinary cancers
- Follow-up outcomes of GUC patients after GS treatment: RCTs, cohort studies, case series, etc.
- Prognostic evaluation models for advanced genitourinary cancers undergoing cytoreductive surgery
- Novel animal models to study cytoreduction treatments for advanced genitourinary cancers
- Novel imaging techniques to assess therapeutic effects of cytoreduction
- Postulated mechanisms of cancer progression after cytoreductive surgery for advanced genitourinary cancers
